Adaptive Biotechnologies (NASDAQ:ADPT) CEO Chad Robins Sells 278,676 Shares

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) CEO Chad Robins sold 278,676 shares of the stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $24.48, for a total transaction of $6,821,988.48. Following the completion of the sale, the chief executive officer directly owned 2,180,518 shares in the company, valued at approximately $53,379,080.64. This represents a 11.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Adaptive Biotechnologies Price Performance

Adaptive Biotechnologies stock opened at $25.49 on Thursday. The stock has a market cap of $4.07 billion, a P/E ratio of -62.17 and a beta of 2.08. The company has a fifty day simple moving average of $21.75 and a 200-day simple moving average of $17.24. Adaptive Biotechnologies Corporation has a 12-month low of $12.00 and a 12-month high of $26.16. The company has a current ratio of 4.79, a quick ratio of 4.68 and a debt-to-equity ratio of 2.22.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its earnings results on Wednesday, July 29th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.12). The business had revenue of $71.55 million during the quarter, compared to analysts’ expectations of $65.44 million. Adaptive Biotechnologies had a negative net margin of 20.73% and a negative return on equity of 36.81%. The business’s quarterly revenue was up 21.5% compared to the same quarter last year. During the same period last year, the company earned ($0.17) EPS. Equities analysts expect that Adaptive Biotechnologies Corporation will post -0.4 EPS for the current fiscal year.

Institutional Trading of Adaptive Biotechnologies

A number of large investors have recently bought and sold shares of ADPT. Caitong International Asset Management Co. Ltd purchased a new position in Adaptive Biotechnologies during the 4th quarter worth $28,000. Allworth Financial LP purchased a new stake in shares of Adaptive Biotechnologies in the second quarter valued at about $35,000. EverSource Wealth Advisors LLC boosted its stake in shares of Adaptive Biotechnologies by 197.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after buying an additional 1,565 shares during the period. KBC Group NV acquired a new stake in shares of Adaptive Biotechnologies during the first quarter worth about $45,000. Finally, Assetmark Inc. boosted its stake in shares of Adaptive Biotechnologies by 867.9% during the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock worth $49,000 after buying an additional 2,708 shares during the period. Institutional investors and hedge funds own 99.17% of the company’s stock.

Wall Street Analyst Weigh In

ADPT has been the topic of a number of recent analyst reports. Guggenheim increased their price objective on Adaptive Biotechnologies from $22.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, July 30th. TD Cowen boosted their target price on Adaptive Biotechnologies from $25.00 to $28.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Piper Sandler boosted their target price on Adaptive Biotechnologies from $20.00 to $27.50 and gave the stock an “overweight” rating in a research note on Tuesday, August 4th. BTIG Research upped their price target on Adaptive Biotechnologies from $24.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Finally, Morgan Stanley increased their price target on shares of Adaptive Biotechnologies from $20.00 to $22.00 and gave the company an “equal weight” rating in a research note on Thursday, July 30th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $24.42.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.